Novo Nordisk India partners with Emcure Pharma to launch Poviztra semaglutide injection 2.4 mg in India

Emcure Pharma becomes the first Indian company with exclusive rights to distribute and commercialise Poviztra®, semaglutide injection 2.4 mg, for weight loss in India
– This partnership is part of Novo Nordisk’s efforts to make its innovative semaglutide molecule accessible to a greater number of people living with overweight and obesity in India.

10 November 2025, Bengaluru: Novo Nordisk India and Emcure Pharma today announced
a strategic partnership to launch Poviztra®, semaglutide injection 2.4 mg, in India. The col-
laboration will strengthen the distribution and marketing of semaglutide for weight loss,
particularly through pharmacies and in regions beyond those currently served by Novo
Nordisk India.

Wegovy® (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated
as an adjunct to a reduced calorie diet and increased physical activity for chronic weight
management and reduction in the risk of major adverse cardiovascular events in individu-
als with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy® experienced
weight loss of over 20%.2 Poviztra® is a second brand of Wegovy®.

This partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments
reach a greater number of patients in India, broadening access to high-quality, safe, and
effective weight management medication. As part of the agreement, Emcure Pharma will
be the exclusive distributor responsible for the commercialisation and marketing of Poviz-
tra®, semaglutide injection 2.4 mg, in India.

Commenting on the partnership, Jay Thyagarajan, Senior Vice President, Region APAC, Novo
Nordisk said, “Obesity is a serious chronic disease affecting millions of people across India and
results in significant unmet medical needs. Recognising the magnitude of the obesity challenge,
we launched Wegovy® in India a few months ago. Now, we are happy to join hands with Emcure
Pharma to broaden access to high-quality, safe, and effective obesity treatment. This partnership
brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s robust marketing
and distribution capabilities to improve access to obesity treatment for people living with over-
weight or obesity in India.”

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma said, “We are
thrilled to partner with Novo Nordisk India to bring Poviztra® to India and are proud to be the
first Indian pharmaceutical company to bring the world’s most widely used and trusted GLP-1-
based weight loss molecule to the Indian market. We believe in the potential of semaglutide.
With our strong understanding of the country’s diverse geographical landscape and established
marketing capabilities, we are confident about making this molecule available to patients who
need it the most.”
Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has strong clinical data and has been ex-
tensively studied across multiple obesity trials in the STEP and SELECT programmes.
Semaglutide as a molecule has been on the market for close to a decade, has 38 million pa-
tient years* of exposure and is supported by robust real-world evidence.1-4.

Disclaimer: This press release is intended solely for informational purposes regarding the medical use of Poviztra® (semaglutide injection 2.4 mg). The reference to “Poviztra®” within this document should not be interpreted as a promotional or advertising message. The use of this medication is strictly contingent upon a licensed healthcare provider’s prescription and clinical judgment. Always consult your healthcare professional for medical advice and treatment options tailored to your individual needs